MarketCap
Facebook
X
Telegram
NeuBase Therapeutics Balance Sheet 2022-2006 | NBSE
Brief overview of NeuBase Therapeutics's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2018 and 2022.
Assets rose from $249.6 thousand to $25.6 million, a gain of +10,149.6%, while CAGR was about 218.2%. The balance sheet expanded rapidly.
Growth in the asset base was not matched by liabilities: +10,149.6% versus +2,424.7%. The balance sheet moved in a more conservative direction.
Equity accounts for 71.2% of assets. Against the initial -16.8%, the capital position looks resilient.
The cash reserve occupies 68% of the balance sheet, previously 100%. It is one marker of short-term resilience.
The accumulated result is -$107.1 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Balance sheet takeaway
NeuBase Therapeutics shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet NeuBase Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -52.4 M | -31.9 M | -10.2 M | -3.68 M | -12.7 M | -12.5 M | -28.6 M | -13.2 M | -5.11 M | -2.61 M | -470 K | - | - | - | - | - |
Long Term Debt |
- | 110 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
469 K | 383 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 250 K | 150 K | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
2.15 M | 4.19 M | 3.15 M | 2.5 M | 41.5 K | 4.93 M | 4.48 M | 3.88 M | 5.27 M | 480 K | 1.09 M | 6.19 M | 1.79 M | - | - | - | - |
Total Liabilities |
7.36 M | 10.1 M | 3.15 M | 2.5 M | 291 K | 5.08 M | 4.48 M | 3.88 M | 5.27 M | 480 K | 1.09 M | 6.19 M | 1.79 M | - | - | - | - |
Retained Earnings |
-107 M | -69 M | -43.6 M | -26.2 M | -42 K | -108 M | -84.3 M | -58.5 M | -43.3 M | -34.2 M | -21.6 M | -21.6 M | -21.6 M | - | - | - | - |
Total Assets |
25.6 M | 64.2 M | 34.4 M | 12.5 M | 250 K | 27.9 M | 29.4 M | 46.4 M | 32 M | 5.74 M | 3.52 M | 1.41 M | 1.41 M | - | - | - | - |
Cash and Cash Equivalents |
17.4 M | 52.9 M | 32 M | 10.3 M | 250 K | 12.8 M | 12.5 M | 28.7 M | 13.2 M | 5.12 M | 2.63 M | 470 K | 422 K | 346 K | - | 197 K | - |
Book Value |
18.2 M | 54.1 M | 31.3 M | 10 M | -41.9 K | 22.8 M | 25 M | 42.5 M | 26.8 M | 5.26 M | 2.43 M | -4.78 M | -382 K | - | - | - | - |
Total Shareholders Equity |
18.2 M | 47.1 M | 31.3 M | 10 M | -41.9 K | 22.8 M | 25 M | 42.5 M | 26.8 M | 5.26 M | 2.43 M | -4.78 M | -382 K | 613 K | 33.2 K | -263 K | -684 K |
All numbers in USD currency
Quarterly Balance Sheet NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
4.83 M | 4.96 M | 5.09 M | 5.21 M | 20.1 K | 49.8 K | 79 K | 79 K | 5.9 M | 5.9 M | 110 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 250 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.86 M | 4.86 M | - |
Total Liabilities |
9.48 M | 11.1 M | 7.01 M | 7.36 M | 9.68 M | 10.6 M | 9.91 M | 9.91 M | 9.04 M | 3.54 M | 2.24 M | 2.24 M | 3.47 M | 3.73 M | 2.85 M | 2.85 M | 752 K | 625 K | 597 K | 530 K | 888 K | 1.73 M | 3.75 M | 3.75 M | 5.74 M | 7.04 M | 3.89 M | 3.89 M | 5.29 M | 3.52 M | 5.28 M | 5.28 M | 3.75 M | 3.28 M | 6.78 M | 6.78 M | 6.77 M | 915 K | 250 K | 250 K | 254 K | 318 K | 2.38 M | 2.38 M | 2.42 M | 2.62 M | 5.53 M | 5.53 M | 5.19 M | 6.19 M | 6.19 M |
Retained Earnings |
-116 M | -115 M | -111 M | -107 M | -95.1 M | -86.6 M | -76.7 M | -76.7 M | -61.8 M | -53.1 M | -47.6 M | -47.6 M | -39.7 M | -35.9 M | -31.5 M | -31.5 M | -124 M | -123 M | -122 M | -1.53 M | -115 M | -114 M | -112 M | -112 M | -103 M | -98.9 M | -91.3 M | -91.3 M | -77.6 M | -69.9 M | -64.7 M | -64.7 M | -54.6 M | -51.3 M | -47.9 M | -47.9 M | -40.2 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M | -21.6 M |
Total Assets |
18.6 M | 22.3 M | 21.5 M | 25.6 M | 40 M | 48.8 M | 57 M | 57 M | 69.3 M | 27.5 M | 30.8 M | 30.8 M | 38.2 M | 7.72 M | 9.88 M | 9.88 M | 8.69 M | 9.63 M | 10.7 M | 137 K | 18.1 M | 19.4 M | 23.4 M | 23.4 M | 33.7 M | 25.7 M | 29.7 M | 29.7 M | 34.3 M | 39.1 M | 44.2 M | 44.2 M | 49.3 M | 51.4 M | 29.4 M | 29.4 M | 35.6 M | 4.24 M | 4.59 M | 4.59 M | 6.86 M | 2.6 M | 2.92 M | 2.92 M | 2.6 M | 1.93 M | 2.07 M | 2.07 M | 1.65 M | 1.41 M | 1.41 M |
Cash and Cash Equivalents |
12.6 M | 14.7 M | 13.8 M | 17.4 M | 29.8 M | 39 M | 47.3 M | 47.3 M | 58.8 M | 24.2 M | 28 M | 32 M | 35.9 M | 5.77 M | 7.73 M | 7.73 M | 1.42 M | 2.13 M | 3.11 M | 137 K | 4.44 M | 5.22 M | 8.72 M | 8.72 M | 18.1 M | 9.52 M | 13.5 M | 13.5 M | 17.6 M | 21.9 M | 25.3 M | 25.3 M | 31 M | 32.8 M | 10.4 M | 10.4 M | 14.9 M | 3.47 M | 4.02 M | 4.02 M | 6.05 M | 1.77 M | 2.07 M | 2.07 M | 1.45 M | 775 K | 1.26 M | 1.26 M | 879 K | 470 K | 1.26 M |
Book Value |
9.14 M | 11.2 M | 14.4 M | 18.2 M | 30.3 M | 38.2 M | 47.1 M | 47.1 M | 60.3 M | 23.9 M | 28.5 M | 28.5 M | 34.7 M | 3.99 M | 7.03 M | 7.03 M | 7.94 M | 9.01 M | 10.1 M | -392 K | 17.2 M | 17.7 M | 19.7 M | 19.7 M | 28 M | 18.6 M | 25.8 M | 25.8 M | 29 M | 35.6 M | 38.9 M | 38.9 M | 45.6 M | 48.2 M | 22.6 M | 22.6 M | 28.8 M | 3.33 M | 4.34 M | 4.34 M | 6.61 M | 2.28 M | 540 K | 540 K | 177 K | -694 K | -3.45 M | -3.45 M | -3.53 M | -4.78 M | -4.78 M |
Total Shareholders Equity |
9.14 M | 11.2 M | 14.4 M | 18.2 M | 30.3 M | 38.2 M | 47.1 M | 47.1 M | 60.3 M | 23.9 M | 28.5 M | 28.5 M | 34.7 M | 3.99 M | 7.03 M | 7.03 M | 7.94 M | 9.01 M | 10.1 M | -392 K | 17.2 M | 17.7 M | 19.7 M | 19.7 M | 28 M | 18.6 M | 25.8 M | 25.8 M | 29 M | 35.6 M | 38.9 M | 38.9 M | 45.6 M | 48.2 M | 22.6 M | 22.6 M | 28.8 M | 3.33 M | 4.34 M | 4.34 M | 6.61 M | 2.28 M | 540 K | 540 K | 177 K | -694 K | -3.45 M | -3.45 M | -3.53 M | -4.78 M | -4.78 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of NeuBase Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
